All Stories

  1. Using read-across to build physiologically-based kinetic models: Part 1. Development of a KNIME workflow to assist analogue selection for PBK modelling
  2. Using Read-Across to build Physiologically-Based Kinetic models: Part 2. Case studies for atenolol and flumioxazin
  3. Evaluation of Urolithin A Efficacy in Heart Failure Patients with Reduced Ejection Fraction: A Randomized, Double-blind, Crossover, Placebo-controlled Clinical Trial
  4. Adherence to the Atrial fibrillation Better Care pathway and the risk of adverse health outcomes in older care home residents with atrial fibrillation: a retrospective data linkage study 2003–18
  5. Supermarket/Hypermarket Opportunistic Screening for Atrial Fibrillation (SHOPS-AF) using sensors embedded in the handles of supermarket trolleys: A feasibility study.
  6. Pharmacist-led intervention for older people with atrial fibrillation in long-term care (PIVOTALL study): a randomised pilot and feasibility study
  7. Managing older people with atrial fibrillation and preventing stroke: a review of anticoagulation approaches
  8. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants
  9. S12 | Finding synergies for 3Rs – toxicokinetics, physiologically-based kinetic (PBK) models and read-across
  10. The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis
  11. Therapeutic drug monitoring: applying the ‘Goldilocks Principle’ to clinical pharmacology
  12. The role of nutraceuticals in heart failure muscle wasting as a result of inflammatory activity. The International Lipid Expert Panel (ILEP) Position Paper.
  13. Metabolic syndrome is associated with similar long-term prognosis in non-obese and obese patients. An analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004-2015 cohort studies
  14. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
  15. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)
  16. Which Statin is Best for the Kidneys?
  17. Statin Intolerance: An Overview for Clinicians
  18. Do antihypertensive medicines increase the risk of depression?
  19. 1208 FEASIBILITY OF A PHARMACIST-LED INTERVENTION FOR ATRIAL FIBRILLATION IN LONG-TERM CARE: THE PIVOTALL STUDY
  20. Abstracts of the 18th Congress of the European Geriatric Medicine Society
  21. Prevalence and outcomes of atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003–2018
  22. Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
  23. Anticoagulation in older people with atrial fibrillation moving to care homes: a data linkage study
  24. 2022: The Year in Cardiovascular Disease – The Year of Upfront Lipid Lowering Combination Therapy.
  25. Adherence to statin therapy - it seems we know everything, yet we do nothing…
  26. Individualized therapy in statin intolerance: the key to success
  27. Factors associated with prescription of oral anticoagulation for atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003–2018
  28. Prevalence and outcomes of atrial fibrillation in older people living in care homes in Wales: a routine data linkage study 2003–2018
  29. Selected Abstracts from Pharmacology 2022
  30. Risk factors for post sternotomy wound complications across the patient journey: A systematised review of the literature
  31. Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel
  32. P17-04 An automated tool for selection of chemical analogues to facilitate development of new physiologically-based kinetic models using a read-across approach
  33. Integrated care for atrial fibrillation management: The role of the pharmacist
  34. 1300 Transfer of outpatient paediatric prescriptions to primary care via the Electronic Prescription Service (EPS)- community pharmacist views
  35. Identifying and addressing pill aversion in adults without physiological‐related dysphagia: A narrative review
  36. Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?
  37. Supermarket/Hypermarket Opportunistic Screening for Atrial Fibrillation (SHOPS-AF): A Mixed Methods Feasibility Study Protocol
  38. Lifetime serum concentration of 25-hydroxyvitamin D 25(OH) is associated with hand grip strengths: insight from a Mendelian randomisation
  39. Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
  40. Prevalence of statin intolerance: a meta-analysis
  41. Homozygous familial hypercholesterolaemia: shedding new light on a rare but deadly condition
  42. Warfarin—Is Self-Care the Best Care?
  43. Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress
  44. Stop and Go: Barriers and Facilitators to Care Home Research
  45. Long-COVID-19: Definition, Epidemiology, and Clinical Implications
  46. CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities
  47. Potential Benefits of Phytochemicals for Abdominal Aortic Aneurysm
  48. The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study
  49. A Systematic Review of Published Physiologically based Kinetic Models and an Assessment of their Chemical Space Coverage
  50. Extreme cardiovascular risk—do we need a new risk category?
  51. Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study
  52. The management of asthma in adult patients in the community pharmacy setting: Literature review
  53. Associations between serum triglycerides and abdominal aortic calcification in a cross-sectional study from the United States of America
  54. Association between ankle-brachial index and cardiovascular mortality in a cohort from the United States of America
  55. The prevalence of statin intolerance worldwide: a systematic review and meta-analysis with 4,143,517 patients
  56. Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study
  57. Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland
  58. Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective
  59. Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta‐analysis of randomized controlled trials
  60. RNA Silencing in the Management of Dyslipidemias
  61. Bacterial lipopolysaccharide–Stoking the fire of residual risk?
  62. Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry
  63. The interaction of Helicobacter pylori with cancer immunomodulatory stromal cells: New insight into gastric cancer pathogenesis
  64. Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice
  65. Statins as anti-pyroptotic agents
  66. Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia
  67. Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors - analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies.
  68. Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations
  69. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP)
  70. Assessment of asthma management in adult patients: A retrospective case-note review in a general practice
  71. Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies
  72. Exploring pharmacists’ views surrounding conscientious objection to abortion and implications in practice
  73. Prevalence of anti-nuclear autoantibodies (ANA) in the general Polish population - analysis of the influence of sex and age on the variability of ANA.
  74. Effects of statins on myocarditis: A review of underlying molecular mechanisms
  75. OPTIMAL USE OF LIPID-LOWERING THERAPY AFTER ACUTE CORONARY SYNDROMES: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
  76. Drucebo effect – the challenge we should all definitely face!
  77. Lipid-lowering therapies: Better together
  78. OUP accepted manuscript
  79. Recent advancements in liposome-based strategies for effective drug delivery to the brain
  80. Management of Statin Intolerance
  81. Statins, COVID-19, and coronary artery disease: killing two birds with one stone
  82. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors
  83. Statins and LDL-C in Secondary Prevention—So Much Progress, So Far to Go
  84. Natural compounds as anti-atherogenic agents: Clinical evidence for improved cardiovascular outcomes
  85. Comparison of LDL-C calculation by friedewald and martin/hopkins methods in 12,243 adults from the United States of America
  86. LDL-C: lower is better for longer—even at low risk
  87. Pharmacist implementation of a treatment pathway for atrial fibrillation in care home residents
  88. The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
  89. Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic
  90. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis
  91. Epigenetic control of atherosclerosis via DNA methylation: A new therapeutic target?
  92. Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice
  93. What's new in lipid‐lowering pharmacology? Integrating basic and clinical research to improve patient outcomes
  94. Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP)
  95. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
  96. The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP)
  97. Liposome Circulation Time is Prolonged by CD47 Coating
  98. Intake of Caffeine and Its Association with Physical and Mental Health Status among University Students in Bahrain
  99. Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants
  100. Application of PLGA nano/microparticle delivery systems for immunomodulation and prevention of allotransplant rejection
  101. Vitamin D and SAMS
  102. Inclisiran—New hope in the management of lipid disorders?
  103. Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications
  104. Statins and Lp(a): do not make perfect the enemy of excellent
  105. The Role of Protein SUMOylation in the Pathogenesis of Atherosclerosis
  106. P705Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel
  107. Warfarin Therapy and Improved Anticoagulation Control by Patient Self-Management
  108. A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome
  109. Regulatory T cells: possible mediators for the anti-inflammatory action of statins
  110. Genetic testing in familial hypercholesterolaemia: What does it add?
  111. Poster Abstracts
  112. Worldwide Dyslipidemia Guidelines
  113. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcomes trials?
  114. Associations between the lipid profile and the development of hypertension in young individuals – the preliminary study
  115. Effects of carbohydrate-restricted diets on low-density lipoprotein cholesterol levels in overweight and obese adults: a systematic review and meta-analysis
  116. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions
  117. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
  118. Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study
  119. Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study
  120. P3836The prognostic accuracy of bleeding risk prediction scores in patients with atrial fibrillation: a systematic review and meta-analysis
  121. P5086Associations between very low concentrations of LDL-Cholesterol, hsCRP and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study
  122. Lipoprotein(a) and the risk of atrial fibrillation – is there a link
  123. The effects of cinnamon supplementation on blood lipid concentrations: A systematic review and meta-analysis
  124. The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis
  125. Autonomic and Autacoid Pharmacology: Goodbye and thank you
  126. Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review
  127. The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials
  128. 3100Effects of morning versus evening statin therapy on lipid profile: a systematic review and meta-analysis
  129. 3104Associations between cardiovascular disease, cancer and very low hdl cholesterol in the reasons for geographical and racial differences in stroke (REGARDS) study
  130. P627Associations between very low concentrations of LDL-cholesterol and health outcomes in the reasons for geographical and racial differences in stroke (REGARDS) Study
  131. Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis
  132. The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis
  133. 220 Daphnia magna as a model for quantifying chaos in cardiac arrhythmia
  134. Relationship between long noncoding RNAs and physiological risk factors of cardiovascular disease
  135. The role of nutraceuticals in the prevention of cardiovascular disease
  136. Evaluating bempedoic acid for the treatment of hyperlipidaemia
  137. Association between telomere length and complete blood count in US adults
  138. D-003 (Saccharum officinarum): The forgotten lipid-lowering agent
  139. Effects of pentoxifylline on inflammatory markers and blood pressure
  140. Sunday 28 August 2016
  141. Monday 29 August 2016
  142. Tuesday 30 August 2016
  143. Bioresorbable scaffold — A magic bullet for the treatment of coronary artery disease?
  144. Autonomic & Autacoid Pharmacology 2016: The year in review
  145. Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases – Some answers and still many questions
  146. Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials
  147. Autonomic & Autacoid Pharmacology: past, present and future
  148. Developing skills to deliver alcohol screening and brief intervention (SBI) in community pharmacy
  149. Lecturing: A lost art
  150. ChemInform Abstract: Synthesis of Antagonists of Muscarinic (M3) Receptors.
  151. Synthesis of antagonists of muscarinic (M3) receptors
  152. Incense – A problematic method of drug-delivery
  153. Activation of β-adrenoceptors mimics preconditioning of rat-isolated atria and ventricles against ischaemic contractile dysfunction
  154. Protective role of β2- and β3-adrenoceptors at reperfusion in isolated rat heart
  155. Vasopressors for cardiopulmonary resuscitation
  156. Effects of hypoxia on the vasodilator activity of nifedipine and evidence of secondary pharmacological properties
  157. The roles of alpha- and beta-adrenoceptor stimulation in myocardial ischaemia